A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis

Exclusion Criteria

• •Medical conditions
• •Skin conditions other than AD that can confound assessments in the area of TEWL assessments in the opinion of the Investigator (ie, skin atrophy, ichthyosis, tinea infection, contact dermatitis).
• •Cracked, crusted, oozing, or bleeding AD lesions in the designated lesional assessment area leaving insufficient skin that is adequate for TEWL assessments.
• •Hypersensitivity to the active substance or to any of the excipients of dupilumab.
• •Ocular disorder that in the opinion of the Investigator could adversely affect the individual's risk for study participation.
• •Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study.
• •History of hypersensitivity reaction to skin tape or adhesives used in tape strip discs.
• •Prior/concomitant therapy
• •Treatment with any investigational medication other than dupilumab within 16 weeks or within 5 half-lives (if known) prior to Day 1, whichever is longer.
• •Systemic AD treatment, cyclosporine A (CsA), systemic corticosteroids, azathioprine (AZA), methotrexate (MTX), mycophenolate mofetil (MMF), or Janus kinase (JAK) inhibitors or phototherapy within 4 weeks of baseline.
• •Topical AD treatment within 1 week of baseline. Face and neck may be treated with topical steroids during the washout period if approved by the Investigator.
• •Participants who received a live vaccine within 4 weeks of baseline. Prior/concurrent clinical study experience
• •Current participation in another investigational or interventional clinical study.
• •The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.